The shares of Strides Arcolab (Strides) surged by 17 per cent to Rs 172.05 after Onco Therapies (OTL), the joint venture between Strides and Aspen Pharmacare Holdings, concluded a licensing and supply agreement with GlaxoSmithKline (GSK).

<tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>Under the agreement, OTL will license intellectual property and supply finished dosage form pharmaceuticals to GSK. OTL will recover the intellectual property development costs from and share the profits with GSK. The stock hit a high of Rs 179.80 and a low of Rs 144. </P></p><p class='TableClas'></p></table>


Strides Arcolab soars on striking in-licensing deal

DALAL STREET SPIKES

Also Read

Dr Reddy`s bets big on drug discovery

Ambanis seek day-to-day hearing of KG gas row

Ranbaxy `wins` case against UK fraud office

Rahul talks development; Lalu lashes out at Oppn

India Inc cheers UPA win, pushes reform agenda

Explore News